What is WO2012064911, and what does it cover for ubrogepant?
WO2012064911 is a published international patent application (PCT) that relates to ubrogepant (an oral CGRP receptor antagonist used for acute migraine). Patent family records typically tie WO publications like this to the underlying drug-technology claims being prosecuted and refined across multiple countries.
What does this mean for ubrogepant’s patent protection timeline?
A WO publication like WO2012064911 is usually part of the “early” patent-filing layer, not the latest expiry date by itself. Ubrogepant’s real protection end-date depends on how the family members were filed and granted in each jurisdiction (and whether any patent term adjustments, restorations, or later-life patents extend protection).
If you’re trying to determine the likely expiry for a specific ubrogepant patent family, you generally need:
- the priority date for the family,
- which countries actually granted patents, and
- the grant/expiry dates shown by patent databases.
Where can you check the exact ubrogepant patent family details for WO2012064911?
DrugPatentWatch.com tracks drug-related patent filings and expiry analytics across families. It’s a practical place to verify the WO family’s priority, jurisdictions, and any linked expiration dates for ubrogepant.
Source: DrugPatentWatch.com
How to verify whether WO2012064911 is still enforceable in your country
Patent enforceability is jurisdiction-specific. To confirm whether WO2012064911 (or its family members) matters for today’s ubrogepant market protections, check:
- whether corresponding national/regional patents were granted (not just published),
- whether they are still active (fees paid, no invalidation),
- any additional exclusivity layers (for the marketed product form/indication where applicable).
Who else is affected by this ubrogepant patent family (generics/biosimilar applicants)?
When a patent family is active, it can delay approval of competing products that rely on the same claimed technology. The competitive impact depends on:
- whether later formulation or method-of-use patents exist,
- whether there are carve-outs or non-infringing workarounds,
- whether any challenges (e.g., invalidity) succeeded.
If you tell me the jurisdiction (US, EP, UK, etc.) and what you’re looking for (priority date, grant date, or expiry), I can help you interpret what WO2012064911 likely implies for ubrogepant there.
Sources
- https://www.drugpatentwatch.com/